| Code | CSB-AP002271HU |
| Abbreviation | Recombinant Human TNFRSF17 protein, partial (Active) |
| MSDS | |
| Size | $142 |
| Order now | |
| Image | |
| Have Questions? | Leave a Message or Start an on-line Chat |
TNFRSF17 (BCMA) serves as a critical receptor for APRIL and BAFF, making it a key therapeutic target in multiple myeloma and B-cell malignancies. This tag-free recombinant human BCMA fragment, spanning residues 5–54 of the extracellular ligand-binding domain, demonstrates confirmed biological activity with an ED50 no greater than 40 ng/ml in inhibiting APRIL-mediated proliferation of anti-IgM-stimulated murine B cells, corresponding to a specific activity exceeding 2.5 × 10⁴ IU/mg. This functional validation supports use in competitive inhibition assays, blocking antibody screening, therapeutic antibody epitope mapping, and ligand-binding interaction studies via ELISA, SPR, or BLI. Expressed in *E. coli* to yield a compact, properly folded domain at >98% purity with endotoxin levels below 1.0 EU/μg, this preparation satisfies the purity and endotoxin criteria typical for cell-based bioassays and drug discovery screening of biologic or small-molecule inhibitors targeting the BCMA–APRIL axis.
There are currently no reviews for this product.